Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Revenue (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Revenue data on record, last reported at $98000.0 in Q3 2025.

  • For Q3 2025, Revenue fell 54.21% year-over-year to $98000.0; the TTM value through Sep 2025 reached $752000.0, down 66.96%, while the annual FY2024 figure was $2.3 million, 64.2% up from the prior year.
  • Revenue reached $98000.0 in Q3 2025 per BTAI's latest filing, down from $120000.0 in the prior quarter.
  • Across five years, Revenue topped out at $1.1 million in Q2 2024 and bottomed at -$3.2 million in Q3 2022.
  • Average Revenue over 4 years is -$32333.3, with a median of $214000.0 recorded in 2024.
  • Peak YoY movement for Revenue: surged 3042.86% in 2023, then crashed 89.13% in 2025.
  • A 4-year view of Revenue shows it stood at $238000.0 in 2022, then surged by 57.98% to $376000.0 in 2023, then dropped by 2.66% to $366000.0 in 2024, then tumbled by 73.22% to $98000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $98000.0 in Q3 2025, $120000.0 in Q2 2025, and $168000.0 in Q1 2025.